Adial Pharmaceuticals, INC 8-K filings

Adial Pharmaceuticals announces potential leadership changes, including the departure of its CEO and CFO, contingent on stockholder approval of certain proposals at the upcoming annual meeting.

Adial Pharmaceuticals has completed the acquisition of Azora Therapeutics, bolstering its pipeline with AT177 for ulcerative colitis and securing up to $64 million in financing.

Adial Pharmaceuticals reports Q1 2026 financial results, highlighting progress in advancing AD04 and potential regulatory advantages for Alcohol Use Disorder treatments.

Adial Pharmaceuticals reports significant regulatory progress for AD04, expanded IP, strategic partnerships, and improved 2025 financial results.

Adial Pharmaceuticals announced a collaboration framework with Molteni Farmaceutici for AD04 commercialization in Europe, potentially worth $60 million, while also reporting a failed Special Meeting of Stockholders due to lack of quorum.

Adial Pharmaceuticals announced it has regained full compliance with Nasdaq's minimum bid price requirement, advancing its AD04 program.

Adial Pharmaceuticals will effect a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and attract broader investor interest.

Adial Pharmaceuticals announces the immediate resignation of James W. Newman, Jr. from its Board of Directors and key committees, with no stated disagreement.

Adial Pharmaceuticals, Inc. announced a warrant inducement transaction with an institutional investor, generating approximately $2.86 million in gross proceeds by exercising existing warrants at a reduced price and issuing new Series F warrants.

Adial Pharmaceuticals reported third quarter 2025 financial results and provided a business update, highlighting progress with its AD04 program for Alcohol Use Disorder following a successful FDA End of Phase 2 meeting.

Adial Pharmaceuticals announced positive FDA feedback on its AD04 Phase 3 clinical trial design for Alcohol Use Disorder, marking a key milestone towards registration.

Adial Pharmaceuticals, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to March 2, 2026.

Adial Pharmaceuticals reports Q2 2025 financial results, highlights successful FDA End of Phase 2 meeting for AD04, and secures manufacturing agreements.

Adial Pharmaceuticals, Inc. has entered into a new 'at-the-market' sales agreement with A.G.P./Alliance Global Partners to sell up to $4.983 million in common stock, replacing a prior agreement with H.C. Wainwright & Co. that generated $4 million in net proceeds.

Adial Pharmaceuticals, Inc. stockholders approved significant corporate governance proposals, including an increase in authorized common stock, an expanded equity incentive plan, and a potential reverse stock split, at their 2025 Annual Meeting.

Adial Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent capital raise, averting potential delisting.

Adial Pharmaceuticals, Inc. believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent $3.6 million capital raise.

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has successfully priced a public offering raising approximately $3.6 million in gross proceeds, while also amending the exercise price and expiration dates of certain existing warrants.

Adial Pharmaceuticals, Inc. has announced a change in the date of its 2025 Annual Meeting of Stockholders to August 1, 2025, while maintaining the previously set record date.

Adial Pharmaceuticals, Inc. has received a non-compliance notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, potentially leading to delisting if a compliance plan is not successfully executed.

Adial Pharmaceuticals announces the date and deadlines for stockholder proposals and director nominations for its 2025 Annual Meeting of Stockholders.

Adial Pharmaceuticals announced its Q1 2025 financial results and provided a business update, highlighting progress in its AD04 clinical program for Alcohol Use Disorder (AUD).

Adial Pharmaceuticals entered into a warrant inducement agreement, generating $2.75 million in gross proceeds for working capital and general corporate purposes.

Adial Pharmaceuticals has replaced its independent auditor, Marcum LLP, with CBIZ CPAs, effective April 28, 2025, following Marcum's resignation.

Adial Pharmaceuticals formalizes Tony Goodman's role as Chief Operating Officer with a three-year employment agreement effective April 1, 2025.

Adial Pharmaceuticals received a notice from Nasdaq for failing to maintain a minimum closing bid price of $1.00 per share, granting them until September 1, 2025, to regain compliance.

Adial Pharmaceuticals announces its 2024 financial results and provides a business update, highlighting progress in its AD04 program for Alcohol Use Disorder (AUD) and advancements towards Phase 3 clinical trials.

Adial Pharmaceuticals announced a positive response from the FDA regarding its proposed in vitro bridging strategy for AD04, a significant step towards Phase 3 clinical trials.

Adial Pharmaceuticals has updated its business development presentation in preparation for upcoming meetings.

Adial Pharmaceuticals has updated its corporate presentation, emphasizing the potential of its AD04 drug for treating Alcohol Use Disorder (AUD) and its progress towards Phase 3 trials.